3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
NET
1
Endocrine
1
Conditions
Small Cell Lung Carcinoma
8
Lung Neoplasms
2
Neuroendocrine Tumors
1
Neuroendocrine Prostate Cancer
1
Neoplasms
1
Extensive Stage Small Cell Lung Cancer
1
Bites and Stings
1
Interventions
lutetium Lu 177 dotatate
34
Everolimus
33
lanreotide
13
gallium Ga 68 dotatate
13
Temozolomide
13
Magnetic Resonance Spectroscopy
13
Nivolumab
12
pembrolizumab
11
Octreotide
11
Capecitabine
11
177Lu-octreotide, DOTA(0)-Tyr(3)-
10
cabozantinib
9
Positron Emission Tomography Computed Tomography
9
3-Iodobenzylguanidine
9
surufatinib
8
Sunitinib
8
Specimen Handling
7
Carboplatin
7
pasireotide
6
amino-acid, glucose, and electrolyte solution
6
90Y-octreotide, DOTA-Tyr(3)-
6
lenvatinib
5
Lutetium-177
5
Ipilimumab
5
Fluorodeoxyglucose F18
5
Etoposide
5
Cisplatin
5
Bevacizumab
5
telotristat ethyl
4
olaparib
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Neuroendocrine Tumors
×
AMG 757
×
Clear all
NCT06502977
2026-04-15
DeLLphi-307
Amgen
Phase 2
Active not recruiting
32 enrolled
9 charts